FGFR4-CART

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug NameFGFR4-CART
Drug Alias Nameanti-FGFR4 CAR‐T cell therapy (Lentigen Technology Inc/ National Institute of Health)RJ-154HLFGFR4-CARTRJ-150HL
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionFibroblast growth factor receptor 4 modulatorsImmunostimulantsT lymphocytes stimulants
TargetsFibroblast growth factor receptor 4
Therapy Area/IndicationsRhabdomyosarcoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesLentigen Technology Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Institutes Of HealthLentigen Technology Inc
Active IndicationsN/A
Inactive IndicationsRhabdomyosarcoma

Other Information

ATC CodeN/A
Related LinksN/A